Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Completed 4Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Unspecified Adult Solid Tumor 1Solid Tumors 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × TIC10 compound × Clear all
NCT03932643 2026-05-28

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

University of Nebraska

Phase 1 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Fox Chase Cancer Center

Phase 1 Completed
33 enrolled
Plasma cell

Multiple Myeloma

NCT02250781 2019-05-22

Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
58 enrolled
Other solid neoplasm

Solid Tumors

NCT02324621 2019-05-22

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
26 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡